- Home
- SBRA vs NGNE Comparison
SBRA vs NGNE Comparison
Compare SBRA & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBRA
- NGNE
- Stock Information
- Founded
- SBRA 2010
- NGNE 2003
- Country
- SBRA United States
- NGNE United States
- Employees
- SBRA N/A
- NGNE N/A
- Industry
- SBRA Real Estate Investment Trusts
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- SBRA Real Estate
- NGNE Health Care
- Exchange
- SBRA Nasdaq
- NGNE Nasdaq
- Market Cap
- SBRA N/A
- NGNE 251.9M
- IPO Year
- SBRA N/A
- NGNE N/A
- Fundamental
- Price
- SBRA $17.88
- NGNE $22.37
- Analyst Decision
- SBRA Buy
- NGNE Buy
- Analyst Count
- SBRA 7
- NGNE 6
- Target Price
- SBRA $19.57
- NGNE $39.83
- AVG Volume (30 Days)
- SBRA 2.7M
- NGNE 213.9K
- Earning Date
- SBRA 05-05-2025
- NGNE 05-09-2025
- Dividend Yield
- SBRA 6.75%
- NGNE N/A
- EPS Growth
- SBRA 185.79
- NGNE N/A
- EPS
- SBRA 0.60
- NGNE N/A
- Revenue
- SBRA $720,247,000.00
- NGNE $925,000.00
- Revenue This Year
- SBRA $6.00
- NGNE N/A
- Revenue Next Year
- SBRA $5.10
- NGNE N/A
- P/E Ratio
- SBRA $29.68
- NGNE N/A
- Revenue Growth
- SBRA 10.76
- NGNE N/A
- 52 Week Low
- SBRA $13.87
- NGNE $6.88
- 52 Week High
- SBRA $20.03
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- SBRA 54.98
- NGNE 68.72
- Support Level
- SBRA $17.13
- NGNE $16.62
- Resistance Level
- SBRA $17.89
- NGNE $18.90
- Average True Range (ATR)
- SBRA 0.35
- NGNE 1.95
- MACD
- SBRA 0.02
- NGNE 0.51
- Stochastic Oscillator
- SBRA 60.98
- NGNE 85.48
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.